#3605. Deficiency of CARMA3 attenuates the development of bleomycin induced pulmonary fibrosis

October 2026publication date
Proposal available till 01-06-2025
4 total number of authors per manuscript0 $

The title of the journal is available only for the authors who have already paid for
Journal’s subject area:
Medicine
Places in the authors’ list:
place 1place 2place 3place 4
FreeFreeFreeFree
2350 $1200 $1050 $900 $
Contract №3605.1 Contract №3605.2 Contract №3605.3 Contract №3605.4
1 place - free (for sale)
2 place - free (for sale)
3 place - free (for sale)
4 place - free (for sale)

Abstract:
Pulmonary fibrosis (PF) has attracted more and more attention due to its irreversibility and high mortality rate. Bleomycin (Bleo), as an alkaline sugar peptide antibiotics, is often used as a first-line anti-tumor agent. Its toxic effect is to induce pulmonary fibrosis (PF) and its clinical symptoms, so it has been widely used in the construction of pulmonary fibrosis model. We found CARMA3 expression in the mice alveolar epithelial cells. And compared with WT mice, CARMA3-KO mice showed reduced deposition of collagen fibers, inflammation and destruction of alveolar epithelial cells in lung tissue. The epithelial-mesenchymal transformation phenotype was also improved in CARMA3-KO mice compared to WT mice. CARMA3 could alleviate the fibrosis by improving inflammation, deposition of collagen and damage of alveolar epithelial cells, which revealed that CARMA3 may be a potential target for pulmonary fibrosis.
Keywords:
CARMA3; Epithelial-mesenchymal transformation(EMT); Inflammation; Pulmonary fibrosis(PF)

Contacts :
0